Disease · MONDO_0006573

lipodystrophy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lipodystrophy. Diseases, record MONDO_0006573. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006573

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lipodystrophy; Open Targets
Open Targets ID: MONDO_0006573; Open Targets
Other names: Inability to make and keep healthy fat tissue, lipodsystrophic syndrome, lipodsystrophic syndromes, lipodystrophy (disease); Open Targets
Disease Ontology: DOID:811; Disease Ontology
MeSH: D008060; MeSH
NCI Thesaurus: C97093; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 8 drugs, from FDA and PMDA; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METRELEPTIN	CHEMBL2107857	Protein	Approval	FDA and PMDA	12	10	6	Drugs and targets
PIOGLITAZONE	CHEMBL595	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ICOMIDOCHOLIC ACID	CHEMBL4297262	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SETMELANOTIDE	CHEMBL3301624	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TIRZEPATIDE	CHEMBL4297839	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FENOFIBRATE	CHEMBL672	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
NIACIN	CHEMBL573	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets57

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
GIPR	Gastric inhibitory polypeptide receptor	1	Gastric inhibitory polypeptide receptor agonist	Phase 2	https://conductscience.org/library/genes/2696	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	1	Glucagon-like peptide 1 receptor agonist	Phase 2	https://conductscience.org/library/genes/2740	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
LEPR	Leptin receptor	1	Leptin receptor agonist	Approval	https://conductscience.org/library/genes/3953	Drugs and targets
MC4R	Melanocortin receptor 4	1	Melanocortin receptor 4 agonist	Phase 2	https://conductscience.org/library/genes/4160	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4537	Drugs and targets

1 to 10 of 57

See all 57 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00246376	Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia	Not applicable	221	2016-03-21	Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis	FENOFIBRATE, NIACIN	Its record names the disease	ClinicalTrials.gov
NCT00025883	Leptin to Treat Lipodystrophy	Phase 2	103	2016-08-16	Lipodystrophy	METRELEPTIN	Its record names the disease	ClinicalTrials.gov
NCT02684591	Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy	Phase 2	50	2019-08-21	Nonalcoholic Fatty Liver Disease, HIV	ICOMIDOCHOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01778556	Short-term Effects of Leptin in People With Lipodystrophy	Phase 2	25	2019-11-13	Lipodystrophy	METRELEPTIN	Its record names the disease	ClinicalTrials.gov
NCT00362440	Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome	Phase 2	9	2017-03-23	HIV Lipodystrophy	METFORMIN, PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT00140244	Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome	Phase 2	7	2017-04-06	HAART-induced Lipodystrophy and Metabolic Syndrome	METRELEPTIN	Its record names the disease	ClinicalTrials.gov
NCT01023620	HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)	Not applicable	4	2019-10-08	HIV Infections	PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT02325674	MEASuRE: Metreleptin Effectiveness And Safety Registry		100		Generalised Lipodystrophy, Partial Lipodystrophy	METRELEPTIN	Its record names the disease	ClinicalTrials.gov
NCT07091734	Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024	Phase 2	32		Lipodystrophy, Partial	TIRZEPATIDE	Its record names the disease	ClinicalTrials.gov
NCT06679270	Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy	Phase 3	24		Familial Partial Lipodystrophy	METRELEPTIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Aramchol 600 mg Orally Daily vs Placebo: deaths from any cause	0 of 25	0 of 25	50	NCT02684591	Trial comparisons
Aramchol 600 mg Orally Daily vs Placebo: serious adverse events	0 of 25	0 of 25	50	NCT02684591	Trial comparisons
r-MetHuLeptin vs Placebo: serious adverse events	0 of 5	0 of 7	12	NCT00140244	Trial comparisons
Leptin vs Pioglitazone or Metformin: serious adverse events	0 of 5	0 of 4	9	NCT00362440	Trial comparisons

Papers from its trials26

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21565796	RESULT	1	PubMed
37595266	DERIVED	1	PubMed
37515588	DERIVED	1	PubMed
37237416	DERIVED	1	PubMed
35820631	DERIVED	1	PubMed
34677608	DERIVED	2	PubMed
34223895	DERIVED	2	PubMed
33890058	DERIVED	1	PubMed
32573497	DERIVED	1	PubMed
32191645	DERIVED	1	PubMed

1 to 10 of 26

See all 26 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006573

GET https://conductscience.org/api/diseases/v1/MONDO_0006573/targets?page=2

API reference For AI assistants